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Summary
Background Since 2006, many countries have implemented publicly funded human papillomavirus (HPV) 
immunisation programmes. However, global estimates of the extent and impact of vaccine coverage are still 
unavailable. We aimed to quantify worldwide cumulative coverage of publicly funded HPV immunisation programmes 
up to 2014, and the potential impact on future cervical cancer cases and deaths.
Methods Between Nov 1 and Dec 22, 2014, we systematically reviewed PubMed, Scopus, and oﬃ  cial websites to 
identify HPV immunisation programmes worldwide, and retrieved age-speciﬁ c HPV vaccination coverage rates up to 
October, 2014. To estimate the coverage and number of vaccinated women, retrieved coverage rates were converted 
into birth-cohort-speciﬁ c rates, with an imputation algorithm to impute missing data, and applied to global population 
estimates and cervical cancer projections by country and income level.
Findings From June, 2006, to October, 2014, 64 countries nationally, four countries subnationally, and 12 overseas 
territories had implemented HPV immunisation programmes. An estimated 118 million women had been targeted 
through these programmes, but only 1% were from low-income or lower-middle-income countries. 47 million women 
(95% CI 39–55 million) received the full course of vaccine, representing a total population coverage of 1·4% (95% CI 
1·1–1·6), and 59 million women (48–71 million) had received at least one dose, representing a total population coverage 
of 1·7% (1·4–2·1). In more developed regions, 33·6% (95% CI 25·9–41·7) of females aged 10–20 years received the 
full course of vaccine, compared with only 2·7% (1·8–3·6) of females in less developed regions. The impact of the 
vaccine will be higher in upper-middle-income countries (178 192 averted cases by age 75 years) than in high-income 
countries (165 033 averted cases), despite the lower number of vaccinated women (13·3 million vs 32·2 million).
Interpretation Many women from high-income and upper-middle-income countries have been vaccinated against 
HPV. However, populations with the highest incidence and mortality of disease remain largely unprotected. Rapid 
roll-out of the vaccine in low-income and middle-income countries might be the only feasible way to narrow present 
inequalities in cervical cancer burden and prevention.
Funding PATH, Instituto de Salud Carlos III, and Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR).
Copyright © Bruni et al. Open Access article distributed under the terms of CC BY.
Introduction
Monitoring of human papillomavirus (HPV) vaccination 
coverage is fundamental to assess the performance of 
vaccination programmes and the potential impact of 
HPV vaccines on HPV-related diseases. Since their 
licensure in 2006, HPV vaccines have been progressively 
introduced in many countries, mainly targeting young 
adolescent girls aged 10–14 years. Comparison of 
coverage statistics is limited by diﬀ erences in age at 
vaccination, programme delivery strategy, and year.1
An HPV vaccination coverage of 70% in women has 
been regarded as the threshold for optimum cost-
eﬀ ectiveness.2 A meta-analysis showed that a vaccination 
coverage of at least 50% delivered a 68% reduction in 
HPV types 16 and 18 and a 61% reduction in anogenital 
warts between the prevaccination and post-vaccination 
periods.3 Coverage will also aﬀ ect the management of 
cervical cancer screening programmes. These 
programmes will need to be adjusted to the number 
of vaccinated females who will enter screening ages.
9 years after the introduction of vaccination, global 
quantiﬁ cation of the number of vaccinated women and 
HPV vaccination coverage is still unavailable. We aimed 
to quantify worldwide cumulative coverage of publicly 
funded HPV immunisation programmes up to 2014, and 
the potential impact on future cervical cancer cases and 
deaths in the vaccinated cohorts. We developed a speciﬁ c 
methodology taking into account variations in national 
guidelines, target ages, ﬁ nancing, and delivery strategies, 
between and within countries at subnational level.
Methods
Data sources
We systematically reviewed the literature and oﬃ  cial 
websites to identify HPV immunisation programmes 
worldwide from June, 2006, to October, 2014.1,4–9 
Identiﬁ cation of data sources was done in two steps 
(appendix p 5). First, scrutiny of oﬃ  cial websites of 
countries with an HPV immunisation programme (eg, 
health departments, national epidemiological centres) was 
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followed by a global review with internet search engines 
between Nov 1 and Dec 22, 2014. Search terms included 
speciﬁ c country names and “HPV”, “vaccine”, 
“immunization calendar” or “cervical cancer” for 
immunisation programmes, and “HPV”, “coverage”, 
“uptake”, “vaccine” for data on coverage. Second, we 
systematically searched PubMed and Scopus from Jan 1, 
2006, to Oct 31, 2014, using MESH terms related to “HPV”, 
“vaccine”, and “coverage”. References cited in retrieved 
articles were also assessed and included if appropriate. 
Publication languages other than English, Spanish, or 
French were assessed using online language translation 
services. Eligibility criteria comprised a detailed description 
of the characteristics of the HPV immunisation 
programmes or the availability of age-speciﬁ c HPV 
coverage data with the date of the estimation. Coverage 
data included oﬃ  cial estimates or survey data. Surveys had 
to include a detailed description of the methodology and 
be representative of the targeted population. Data were 
extracted by two independent investigators (LB and LB-R), 
with discrepancies resolved by forced consensus.
Procedures
For HPV immunisation programmes, we retrieved 
information about year of introduction, target ages, the 
vaccination schedule, and other features of speciﬁ c 
programmes (appendix pp 17–29). We subdivided each 
immunisation programme into two possible imple-
mentation strategies: primary and catch-up. Both 
strategies could use either an organised or an 
opportunistic approach (appendix p 26). For each 
immunisation programme and strategy, we derived the 
birth cohorts that had been targeted by the end of 2014. 
We considered subnational variations in Belgium, 
Canada, Italy, Spain, Switzerland, and the UK.
For HPV vaccination coverage rates, we obtained data 
for one-dose, two-dose, and three-dose HPV vaccine 
coverage by country and birth cohort (appendix pp 30–35). 
If data were not originally reported by birth cohort, we 
converted retrieved coverage rates into birth-cohort-
speciﬁ c rates from the population age and the year of the 
estimation. We made an eﬀ ort to obtain vaccination 
coverage by single year of age. When coverage rate was 
only available for a speciﬁ c age group, that rate was 
assigned to all relevant birth cohorts. When there were 
discrepancies among multiple sources, oﬃ  cial estimates 
prevailed or, in the absence of oﬃ  cial estimates, we 
selected the most representative sample.
Female population data by birth cohort and country 
were obtained annually for the years 2010–2100 from 
the UN Population Division, or from the US Census 
Bureau when unavailable from the UN.10,11 For 
Research in context
Evidence before this study
Since 2006, many countries have introduced human 
papillomavirus (HPV) vaccines through national immunisation 
programmes. Vaccination coverage is a key indicator to assess 
programme performance and to monitor the potential impact 
of HPV vaccines on HPV-related diseases. Many countries 
produce HPV immunisation statistics from administrative data 
or representative surveys. However, these data are 
disseminated throughout miscellaneous sources and are 
non-standardised. Comparison of coverage statistics is limited 
by diﬀ erences in age at vaccination, programme delivery 
strategy, and year. Country-speciﬁ c coverage rates could range 
from less than 5% to more than 80%. 9 years after vaccine 
introduction, global estimates of vaccination coverage using 
appropriate methodology are still unavailable and the number 
of vaccinated women in the world is unknown.
Added value of this study
We present the ﬁ rst estimates of global HPV vaccination 
coverage up to October, 2014. We have developed a speciﬁ c 
method to address comparability limitations and appropriately 
combine coverage statistics. Methods comprise the 
compilation of the most comprehensive database to date on 
publicly funded national HPV immunisation programmes, 
including conversion of all retrieved coverages from multiple 
sources into birth-cohort-speciﬁ c coverages, design of an 
imputation algorithm to treat missing data, and use of global 
population estimates and projections. These procedures allow 
continuous monitoring and production of vaccination coverage 
trends, together with the use of cancer statistics to approximate 
the expected reduction on cervical cancer in vaccinated cohorts.
Implications of all the available evidence
By October, 2014, 64 countries nationally, four countries 
subnationally, and 12 overseas territories have introduced the 
HPV vaccine into their national immunisation programmes, 
mostly in high-income and upper-middle-income settings. 
Globally, we estimate that 47 million women received a full 
course of HPV vaccine between 2006 and 2014, and 59 million 
women received at least one dose, representing 39·7% and 
50·1% of the targeted female cohorts, respectively. Behind 
these statistics there are huge diﬀ erences not only in global 
distribution by development level, but also in the performance 
of HPV immunisation programmes. Individually, many 
countries with a national HPV vaccination programme achieve 
high coverage rates, mostly in the younger cohorts, but older 
cohorts and large countries with poorer performances 
contribute to lowering of the overall coverage estimates. The 
most vulnerable populations, which would beneﬁ t most from 
vaccination, still remain unprotected. Access to HPV 
vaccination in low-income and lower-middle-income countries 
is almost non-existent, despite these countries carrying most of 
the burden of cervical cancer cases worldwide.
Articles
www.thelancet.com/lancetgh   Vol 4   July 2016 e455
subnational regions, we applied the regional population 
weight to the national estimate. Estimates of cervical 
cancer incidence and mortality rates by 5 year age 
groups and country were obtained from GLOBOCAN 
2012, produced by the International Agency for Research 
on Cancer (IARC).12
Statistical analysis
We grouped countries with the UN classiﬁ cation 
system, which categorises the world into ﬁ ve macro-
geographical (continental) regions and 22 geographical 
subregions.13 We also classiﬁ ed countries by income 
level with the World Bank’s classiﬁ cation.14 We calculated 
full-course coverage as the proportion of individuals in 
the targeted birth cohorts who received the complete 
three-dose HPV vaccine (or a minimum of two doses 
within at least 6 months if that was the recommended 
schedule in the immunisation programme). We 
calculated one-dose coverage as the proportion of 
individuals in the targeted birth cohorts who received at 
least one dose of HPV vaccine.
Appendix pp 6, 36, and 37 present the diﬀ erent stages 
in the methodology to calculate global ﬁ gures and their 
assumptions. We identiﬁ ed 1922 birth cohorts from 
75 countries covered by an HPV immunisation 
programme anytime between 2006 and 2014. Coverage 
data were available for only 645 birth cohorts from 
39 countries. We used an iterative procedure to impute 
values for missing data (appendix pp 1, 2).  This 
procedure comprised an eight-step process that 
assigned the previous or subsequent birth cohort 
coverage estimate to the missing coverage 
(appendix pp 8–10, 38). In countries with no coverage 
reported, we imputed a cross-country weighted average 
by implementation strategy, age at vaccination, 
geographical region, and income level. In birth cohorts 
in which only full-course or one-dose coverage was 
reported, we derived the missing dose-speciﬁ c coverage 
from those available with a regression model based 
on 444 birth cohorts with complete information 
(appendix pp 1, 2, 7). Appendix pp 1 and 2 also present a 
comprehensive evaluation of the validity of the missing 
data treatment methods. To provide an estimation of the 
uncertainty of the parameters, we computed 95% CIs 
with the percentile method in a bootstrap process with 
3000 replications using Stata (version 13).15
We calculated the expected number of new cervical 
cancer cases or deaths up to age 74 years by multiplying 
the contemporary age-speciﬁ c incidence and mortality 
rates12 by the corresponding expected annual population 
for 2013, 2014, and onwards, until the year of the 
75th birthday by birth cohort, age, and country.10 We 
Figure 1: Countries that have introduced a publicly funded national human papillomavirus vaccination programme since 2006, by year
Striped sections indicate implementation in a part of the country. French Polynesia, Liechtenstein, and Niue have reported vaccine programmes, but no information 
was available about year of introduction. *Special territory. †Partial implementation.
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computed the cumulative number of cases prevented by 
multiplying individual HPV vaccination coverages by the 
number of expected cancer cases for each birth cohort 
and year up to age 74 years (appendix pp 3, 4). For both 
full-course and one-dose HPV vaccination, we assumed 
70% vaccine eﬀ ectiveness (100% eﬃ  cacy against HPV 
types 16 and 18, which are the cause of 70% of cervical 
cancer cases worldwide).16 Appendix pp 36 and 
37 summarise all the methods and general assumptions 
of each step in the process.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all 
data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
From June, 2006, to October, 2014, 64 countries nationally, 
four countries subnationally, and 12 overseas territories 
had implemented HPV immunisation programmes 
(ﬁ gure 1). The most frequently targeted age was 12 years 
(non-exclusively) in 57 (71·8%) programmes, followed by 
11 years in 37 (47·4%) programmes, 13 years in 29 (37·2%) 
programmes, 9 years in 15 (19·2%) programmes, and 
14 years in 14 (17·9%) programmes (appendix pp 17–29). 
Of 62 programmes with information, 42 (67·7%) 
programmes delivered the vaccine through schools, but 
most allowed vaccination at primary health-care centres 
or other health-care facilities to complement the 
programme (appendix pp 17–29). In 2014, at least 
20 countries introduced a two-dose schedule for girls 
younger than 15 years following new WHO 
recommendations.17 Before this time, Canada, Mexico, 
and Switzerland had previous established alternative 
schedules to the three-dose standard (appendix pp 17–29).
We estimated that 118 million women worldwide had 
been targeted by an HPV immunisation programme at 
some point between 2006 and 2014: 62 million as a 
primary target, 12·5 million by organised catch-up, and 
43 million by opportunistic catch-up (appendix p 15). 
These numbers represent 3·5% of females globally, 
8·7% of those aged 15–26 years, and 11·9% of those aged 
10–14 years. Females born between 1994 and 2004 
(aged 10–20 years old in 2014) were the most common 
vaccine target cohorts in the primary programmes 
(appendix p 15).
Appendix p 16 shows the gradual introduction of HPV 
vaccination according to the annual number of cervical 
cancer cases and socioeconomic development level. 82% 
of targeted women (97 million) were from more developed 
regions and 18% (21 million) were from less developed 
regions with a later introduction (appendix p 16). Only 
seven (18%) of 38 less developed countries implemented 
HPV immunisation programmes before 2010. These 
countries targeted fewer birth cohorts on average than did 
more developed regions (mean 6·7 [SD 5·6] vs 10·7 [6·0] 
cohorts; p=0·0031).
An estimated 47 million (95% CI 39–55 million) 
women worldwide were vaccinated against HPV (full 
course) through immunisation programmes by 2015 
(table). This number represents 1·4% (95% CI 1·1–1·6) 
of the female population and 6·1% (4·9–7·4) of females 
aged 10–20 years (table). Globally, coverage among the 
118 million targeted females (aged 9–45 years) was 
39·7% (95% CI 33·0–46·8) increasing to 54·9% 
(45·1–65·4) among primary targets and organised 
catch-ups (table). An additional 12 million women were 
estimated to have received one dose of HPV vaccine, 
accounting for a total of 59 million (95% CI 
48–71 million) women worldwide having received at 
least one dose of HPV vaccine, 1·7% (95% 1·4–2·1) of 
the female population, 7·5% (5·9–9·2) of females aged 
10–20 years, and 50·1% (40·7–60·0) of targeted females 
(table).
Most targeted and subsequently vaccinated women 
were from high-income countries (68%) or upper-
middle-income countries (28%, and mainly from Latin 
America; ﬁ gures 2, 3). In high-income countries, by 
2014, 32% of females aged 10–20 years had received the 
full course of HPV vaccine and 41% had received at least 
one dose (table). By contrast, 19% of Latin American 
females aged 10–20 years had received the full course of 
vaccine and 22% had received at least one dose (table). 
Only 1·4 million vaccinated women were from 
low-income and lower-middle-income countries, 
representing global coverage of 2·7% among 
10–20-year-old females in less developed regions, 
compared with 33·6% in more developed regions 
(table). Although few cohorts had been vaccinated 
in low-income and lower-middle-income countries, 
estimated coverage among targeted cohorts was high 
(89%; table).
Figure 4 and appendix pp 43–46 show HPV vaccine 
coverage rates by geographical region, age, and strategy. 
Northern Europe and Australia and New Zealand 
presented the highest age-speciﬁ c coverage rates, 
reaching 69% of females currently aged 15–19 years. In 
Central America, South America, and southern Africa, 
almost all vaccinated females were in the younger age 
group (aged 10–14 years). Oceania had the highest 
coverage estimates globally, accounting for 17% of all 
females in Australia and New Zealand and 10% in 
Micronesia (ﬁ gure 4, appendix).
We calculated that about 379 000 cases (95% CI 
368 000–391 000) of cervical cancer and 156 000 deaths 
(151 000–161 500) by age 75 years could be averted in the 
47 million fully vaccinated women (ﬁ gure 5), assuming 
lifelong protection. For a 10% increase or decrease in 
vaccine eﬀ ectiveness, the number of new cases would 
vary by 54 145 worldwide. These estimates increased to 
about 444 600 cases (95% CI 431 000–458 500) and 
184 000 deaths (177 000–191 000) when we considered 
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one-dose vaccination data. The number of cancer cases 
prevented showed the same distribution when assessed 
by income (ﬁ gure 5). Despite a lower number of 
vaccinated women in upper-middle-income countries 
than in high-income countries, the higher incidence of 
cervical cancer translates into a higher expected impact, 
with 178 192 cases prevented by age 75 years in 13 million 
fully vaccinated females (ﬁ gure 5).
To assess the potential eﬀ ect of our imputation system, 
we did a comprehensive sensitivity analysis of our missing 
data treatment (appendix pp 1, 2). First, we ran 
50 simulations in each of which we drew a random sample 
of 100 birth cohorts to impute (appendix p 11). Results 
showed a correlation index of 0·81 (range 0·63–0·95) 
between imputed and original data. Second, we did a new 
literature search between Nov 15 and Nov 20, 2015, and 
updated a set of 61 birth cohorts with new original data, 
showing a response correlation of 0·79 (95% CI 
0·66–0·88; appendix p 12). Finally, we did a sensitivity 
analysis considering diﬀ erent coverage scenarios ranging 
from 0% to 100% for countries without data (appendix 
pp 13, 14, 40). The global estimate of 47 million vaccinated 
women ranged from 39 million to 51 million in the most 
extreme scenarios. The impact of these imputations was 
more prominent in upper-middle-income countries, 
where the number of vaccinated women ranged from 51% 
lower to 19% higher than in high-income countries. 
However, in high-income countries, which contributed 
the largest number of vaccinated women (70%), the 
impact was almost negligible.
Number of vaccinated 
females (millions)
Coverage among the total female population Coverage among the targeted population (all ages)
All ages Aged 10–20 years All Primary target and 
organised catch-up
Opportunistic catch-
up*
Full-course vaccination
Worldwide 46·9 (39·0–55·3) 1·4% (1·1–1·6) 6·1% (4·9–7·4) 39·7% (33·0–46·8) 54·9% (45·1–65·4) 13·3% (6·8–21·0)
Less developed regions 15·0 (10·4–20·3) 0·5% (0·4–0·7) 2·7% (1·8–3·6) 71·3% (49·6–96·6) 73·7% (50·9–100·0) 21·2% (12·9–29·6)
More developed regions 31·9 (25·7–38·7) 5·4% (4·4–6·5) 33·6% (25·9–41·7) 32·9% (26·5–39·8) 48·0% (38·2–58·5) 13·1% (6·7–21·5)
Full-course vaccination by income
High income 32·2 (26·2–38·9) 5·4% (4·4–6·5) 32·1% (25·0–39·9) 33·6% (27·3–40·6) 48·5% (38·6–59·3) 13·8% (7·3–22·4)
Upper middle income 13·3 (8·9–18·6) 1·1% (0·7–1·6) 7·2% (4·8–10·1) 64·6% (43·0–90·1) 70·8% (47·0–98·9) 3·5% (2·2–4·7)
Lower middle income 0·3 (0·2–0·5) 0·0% (0·0–0·0) 0·1% (0·1–0·2) 69·6% (42·1–100·0) 69·6% (42·1–100·0) ··
Low income 1·0 (0·7–1·4) 0·3% (0·2–0·4) 1·0% (0·7–1·4) 95·2% (60·3–100·0) 95·2% (60·3–100·0) ··
Full-course vaccination by geographical region
Africa 1·6 (0·9–2·6) 0·3% (0·2–0·5) 1·2% (0·7–2·0) 88·0% (46·5–100·0) 88·0% (46·5–100·0) ··
Asia 4·2 (2·4–6·3) 0·2% (0·1–0·3) 1·1% (0·6–1·7) 57·2% (32·6–85·5) 62·5% (34·0–95·4) 21·4% (14·3–28·9)
Europe 14·0 (12·0–16·1) 4·3% (3·7–5·0) 31·1% (26·1–36·5) 39·2% (33·7–45·2) 52·8% (44·5–61·7) 11·7% (8·5–15·3)
Latin America and Caribbean 11·6 (7·1–16·6) 3·8% (2·3–5·4) 19·0% (11·6–27·3) 71·0% (43·6–100·0) 71·0% (43·6–100·0) 3·8% (2·1–5·8)
Northern America 13·1 (8·0–18·9) 7·3% (4·5–10·5) 35·6% (18·5–56·6) 24·6% (15·1–35·5) 39·3% (20·5–62·5) 13·7% (5·3–25·1)
Oceania 2·4 (1·6–3·3) 12·7% (8·6–17·3) 35·9% (18·8–56·0) 62·2% (42·1–84·6) 62·2% (42·1–84·6) ··
One-dose vaccination
Worldwide 59·2 (48·1–70·9) 1·7% (1·4–2·1) 7·5% (5·9–9·2) 50·1% (40·7–60·0) 67·3% (53·9–81·7) 20·2% (10·5–31·6)
Less developed regions 17·0 (11·2–23·8) 0·6% (0·4–0·8) 3·0% (2·0–4·3) 80·6% (53·1–100·0) 83·2% (54·4–100·0) 25·5% (15·6–35·6)
More developed regions 42·3 (33·2–52·2) 7·1% (5·6–8·8) 43·3% (32·0–55·3) 43·5% (34·1–53·7) 61·5% (47·0–76·8) 20·1% (10·4–32·8)
One-dose vaccination by income
High income 42·6 (33·6–52·3) 7·1% (5·6–8·8) 41·3% (30·9–52·9) 44·4% (35·0–54·5) 62·1% (47·8–77·5) 20·9% (11·2–33·8)
Upper middle income 15·3 (9·7–22·0) 1·3% (0·8–1·9) 8·3% (5·2–12·0) 74·4% (46·9–100·0) 81·4% (51·1–100·0) 5·2% (3·2–7·1)
Lower middle income 0·4 (0·2–0·6) 0·0% (0·0–0·0) 0·1% (0·1–0·2) 76·5% (46·5–100·0) 76·5% (46·5–100·0) ··
Low income 0·9 (0·5–1·4) 0·2% (0·1–0·3) 0·9% (0·5–1·4) 86·1% (43·9–100·0) 86·1% (43·9–100·0) ··
One-dose vaccination by geographical region
Africa 1·6 (0·8–2·7) 0·3% (0·1–0·5) 1·2% (0·6–2·0) 85·2% (40·9–100·0) 85·2% (40·9–100·0) ··
Asia 4·6 (2·7–6·9) 0·2% (0·1–0·3) 1·2% (0·7–1·8) 62·8% (36·1–93·7) 68·3% (37·3–100·0) 25·6% (17·3–34·4)
Europe 16·7 (14·3–19·3) 5·2% (4·4–6·0) 36·4% (30·3–42·9) 46·9% (40·1–54·3) 62·3% (52·1–73·0) 15·8% (11·5–20·7)
Latin America and Caribbean 13·5 (7·8–19·9) 4·4% (2·5–6·4) 22·1% (12·7–32·6) 82·4% (47·8–100·0) 82·5% (47·8–100·0) 13·3% (7·2–20·1)
Northern America 20·0 (12·3–29·0) 11·2% (6·9–16·2) 53·4% (27·1–85·6) 37·6% (23·2–54·6) 59·0% (29·9–94·5) 21·7% (8·9–38·7)
Oceania 2·8 (1·9–3·9) 15·0% (10·1–20·4) 41·1% (21·5–64·0) 73·2% (49·4–99·6) 73·2% (49·4–99·6) ··
Data in parentheses are 95% CIs. *Not implemented in some countries in a group.
Table: Estimated number of vaccinated females and human papillomavirus vaccine coverage by October, 2014 
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Discussion
Since the licensure and progressive introduction of 
HPV vaccines in 2006, this is, to our knowledge, the 
ﬁ rst attempt to estimate current HPV vaccination 
coverage globally and the corresponding reduction in 
cervical cancer incidence and mortality among currently 
vaccinated women. We provide a comprehensive 
description of HPV immunisation programmes 
worldwide. We base all our analyses on the use of birth 
cohorts, an approach that circumvents the comparability 
limitations posed by the heterogeneous data available 
for HPV vaccines. This method can be used to monitor 
trends in HPV vaccination coverage. Our results show 
high disparities in vaccine implementation and 
numbers of vaccinated women according to income 
level of countries.
Despite accounting for only 14% of annual cervical 
cancer cases, on the basis of our estimations, high-
income countries accounted for almost 70% of vaccinated 
women worldwide by the end of 2014. Due to the high 
initial prices of the vaccines, only high-income countries 
could aﬀ ord them. Furthermore, these same countries 
had already largely invested in cervical cancer screening 
programmes that were successful in lowering and 
stabilising cervical cancer rates.18 Redoubling eﬀ orts, 
most (69%) high-income countries have progressively 
introduced HPV vaccination in these years, mostly to 
pre-adolescent females, but some extended the coverage 
to older cohorts using catch-up strategies. High-quality 
cervical cancer screening and HPV vaccination—the 
most comprehensive prevention strategies against 
cervical cancer—are currently deployed in combination 
in high-income countries. However, high-income 
countries show the lowest levels of vaccination coverage 
among targeted primary groups, achieving globally less 
than 50% coverage, mostly due to the strong inﬂ uence of 
underperforming countries such as the USA, France, or 
Germany in the ﬁ nal estimates.
Other countries that have introduced HPV vaccination 
in the past few years are Latin American (48% of 33 Latin 
American countries). Most of these countries are upper-
middle-income countries with high incidence rates 
of cervical cancer despite long-term screening 
programmes. Screening has not had the expected 
impact, even with the high coverage rates of cervical 
cytology achieved, because women do not universally 
access proper follow-up and treatment.19 Many of these 
countries are now introducing HPV vaccination 
focusing on one or two cohorts of females. HPV vaccine 
introduction outside high-income and Latin American 
countries is scant: only some middle-income countries 
(Paciﬁ c countries, South Africa, Libya, Seychelles, 
Malaysia, some Kazakhstan regions, Macedonia, and 
Bulgaria) and three GAVI-eligible countries (Bhutan, 
Lesotho, and Rwanda) have started HPV immunisation 
programmes. Romania initiated a publicly funded 
school-based programme targeting 10–11 year olds that 
Figure 2: Female population pyramid by development level and age distribution of women targeted by 
national HPV vaccination programmes
We grouped countries with the UN classiﬁ cation system.13 More developed regions comprise Europe, northern 
America, Australia and New Zealand, and Japan. Less developed regions comprise all regions of Africa, Asia (except 
Japan), Latin America and the Caribbean, plus Melanesia, Micronesia, and Polynesia. HPV=human papillomavirus. 
*Birth cohorts of women are shown in parentheses.
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reached only 2% coverage in the ﬁ rst year, and, after 
several attempts to improve the uptake, it was ﬁ nally 
suspended.7
Countries that have not yet introduced the vaccine are 
those that can gain the most in terms of health beneﬁ ts.20 
Our analysis of the expected averted cervical cancer cases 
in these vaccinated cohorts shows that, in upper-middle-
income countries, vaccination of 13·3 million women is 
expected to reduce more cervical cancer cases than would 
vaccination of 32·2 million women in high-income 
countries. Eﬀ orts should pursue vaccine introduction in 
all these low-income and middle-income countries, 
where screening has been neither successful nor 
implemented and vaccination remains the only feasible 
preventive option. For less developed countries, many 
women have been vaccinated through demonstration 
projects, such as the Gardasil Access Program, which has 
shipped 1·3 million doses to 21 countries—enough to 
vaccinate more than 445 900 eligible women.21,22 PATH 
undertook four demonstration projects between 2008 
and 2011, targeting 52 755 women from Peru, Uganda, 
Vietnam, and India.23 GAVI, the Vaccine Alliance, is 
supporting more than 20 demonstration projects in 
developing countries for the 2013–15 period (mostly in 
sub-Saharan Africa) where about 400 000 women will 
beneﬁ t from vaccination.24 GAVI demonstration projects 
will provide an opportunity for low-income and lower-
middle-income countries and could represent a gateway 
for national introduction. However, only low-income 
countries and 40% of lower-middle-income countries fall 
Figure 3: Female population pyramid of women targeted by national HPV vaccination programmes by income
Income classiﬁ cation follows World Bank classiﬁ cation of the world’s economies based on estimates of gross national income (GNI) per head for the previous year.14 As of July 1, 2014, low-income 
economies are deﬁ ned as those with a GNI per head, calculated with the World Bank Atlas method, of US$1045 or less in 2013; middle-income economies are those with a GNI per head of more than 
$1045 but less than $12 746; high-income economies are those with a GNI per head of $12 746 or more. Lower-middle-income and upper-middle-income economies are separated at a GNI per head of 
$4125. Low-income and middle-income economies are sometimes referred to as developing economies. Proportion of cervical cancer cases calculated from GLOBOCAN 2012, produced by the 
International Agency for Research on Cancer.12 HPV=human papillomavirus. *Birth cohorts of women are shown in parentheses.
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into GAVI eligibility criteria. Without further support, 
GAVI non-eligible countries could face many obstacles in 
the introduction of vaccination due to aﬀ ordability issues 
and competing health needs.
We recorded large heterogeneity in programme design 
and performance. Coverage levels varied between 
countries and subnationally within countries. School-
based programmes have been reported to achieve the 
highest coverage.25 Social norms and values related to 
sexual activity, and trust in vaccination programmes and 
health-care providers, are other key factors associated 
with the uptake.25,26 In the USA, HPV vaccination did not 
reach the same levels of uptake as other adolescent 
immunisations, such as meningococcal ACWY and 
varicella.27 By contrast, Australia is a model of success 
that has already demonstrated ﬁ rst beneﬁ ts of 
vaccination, with coverage levels reaching 70% in 
targeted young adolescent females and more than 50% 
in older catch-up cohorts.28 Little information is available 
about coverage outside HPV immunisation programmes. 
Sweden reported one-dose coverage rates ranging from 
3·5% to 9·4% among females born between 1986 and 
1989 outside HPV immunisation programmes, 
compared with 82·3% of those born in 2001 and included 
in immunisation programmes.29
On average, countries from developing regions reached 
higher vaccination coverage levels than did those in 
developed regions. In some developing countries, 
estimated national coverage levels were based on previous 
demonstration projects, which reached high coverage 
rates and might be outperforming relative to on-the-
ground implementation.21,23,30,31 Of 21 HPV demonstration 
projects from 14 countries, 60% were managed by the 
Ministry of Health, and the overall uptake rate was 
88·7%.21 Targeted females from less developed regions 
were younger and mainly reached by primary programmes 
(68%), whereas targeted females from more developed 
regions were older and 44% were reached by means of 
opportunistic strategies. Northern America and eastern 
and western Europe were the regions with coverage levels 
less than 50% among the primary target groups.
From a methodological point of view, one of the main 
challenges in aggregation and compiling of country data 
into global coverage estimates is the variability in the age 
of vaccination among cohorts.32 Birth cohorts have the 
advantage that they can be calculated from the date of the 
coverage estimation and the reported age of vaccinated 
individuals; they also provide clearly identiﬁ able 
denominators (population statistics). However, use of 
population denominators instead of the actual number of 
targeted and vaccinated women might be subject to 
overestimation or underestimation. By 2014, vaccine 
manufacturers reported distributing more than 
175 million doses worldwide.33 These ﬁ gures are 
consistent with our estimates, even despite our 
approximation including neither distributed doses that 
are not ﬁ nally administered nor the number of women 
vaccinated outside HPV immunisation programmes. 
Figure 4: Estimated full-course coverage of human papillomavirus vaccine by 2014, by age group and geographical region
Error bars represent 95% CIs. Regions without bar charts had no or very low estimated coverage. More detailed data are provided in the appendix (pp 43–46). 
Countries included in the analysis are geographically classiﬁ ed as follows: northern Africa (Libya); eastern Africa (Rwanda, Seychelles, Uganda); southern Africa 
(Lesotho, South Africa); Caribbean (Barbados, Cayman Islands, Dominican Republic, Trinidad and Tobago, US Virgin Islands); Central America (Mexico, Panama); 
South America (Argentina, Brazil, Chile, Colombia, Guyana, Paraguay, Peru, Suriname, Uruguay); northern America (Bermuda, Canada, Greenland, USA); central Asia 
(Kazakhstan); eastern Asia (Japan); southern Asia (Bhutan); southeastern Asia (Brunei, Malaysia, Singapore); western Asia (Israel, United Arab Emirates); eastern 
Europe (Bulgaria, Czech Republic, Romania, Russia); northern Europe (Denmark, Finland, Iceland, Ireland, Latvia, Norway, Sweden, UK); southern Europe (Gibraltar, 
Greece, Italy, Malta, Portugal, San Marino, Slovenia, Spain, Macedonia); western Europe (Austria, Belgium, France, Germany, Luxembourg, Monaco, Netherlands, 
Switzerland); Australia and New Zealand (Australia, New Zealand); Melanesia (Fiji, New Caledonia); Micronesia (Guam, Kiribati, Marshall Islands, Micronesia, 
Northern Mariana Islands, Palau); Polynesia (American Samoa, Cook Islands).
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Immunisation coverage estimates basically derive from 
oﬃ  cial estimates from administrative data systems or 
from representative surveys. Both data sources are subject 
to some biases.34,35 Vaccination data are politically sensitive 
and thus might be prone to data manipulation, especially 
when funding is based on performance.36 Moreover, 
publication bias in government data should be considered, 
by which positive coverage might be highly disseminated 
and negative results less available. Surveys and non-
oﬃ  cial sources could identify those cases.37 Our coverage 
estimates were usually extracted from only one source. 
When additional sources were available, few discrepancies 
were found and oﬃ  cial estimates were commonly 
selected. In 60% of cases, sources were governmental 
(statistics, press notes, reports, or oﬃ  cial epidemiological 
bulletins), and 30% of cases were scientiﬁ c publications.
Figure 5: Cervical cancer cases before age 75 years in the cohort of women targeted by HPV vaccination programmes by the end of 2014
(A) Estimated incident cervical cancer averted before age 75 years in the 118 million women ever targeted by HPV vaccination programmes. Solid line shows the 
cumulative number of expected cervical cancer cases up to age 74 years if targeted cohorts would not have been vaccinated. Dashed line shows the cumulative 
number of expected cervical cancer cases up to age 74 years in targeted cohorts considering current HPV vaccination coverage. (B) Estimated incident cervical cancer 
averted before age 75 years in the 47 million fully vaccinated women by income level. Figure shows the cumulative number of expected cervical cancer cases up to age 
75 years in vaccinated women assuming 70% vaccine eﬀ ectiveness.
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However, our most important challenge and limitation 
was missing data. We could not retrieve any information 
about coverage levels for 32 countries and had to impute 
them with the average rate of the remaining countries 
with the same year, age at vaccination, geographical 
region, and income level. Importantly, the contribution to 
global estimates of these 32 countries was relatively low, 
representing only 2% of targeted women. These countries 
were more likely to have recently started vaccination and 
therefore had few targeted birth cohorts, and 60% were 
territories or countries with small populations. More than 
half of the global and high-income country estimates 
were based on the original data retrieved. However, use of 
imputed data increased in the rest of the regions, 
increasing also the uncertainty of our estimates. On the 
basis of the results of our comprehensive sensitivity 
analysis of missing data treatment, we can conclude that 
the performance of our sophisticated imputation system 
was more than acceptable, particularly in high-income 
countries and globally.
Despite the high number of women successfully 
vaccinated worldwide between 2006 and 2014 worldwide, 
many populations have still not yet had the opportunity 
to be vaccinated. Notably, current HPV immunisation 
programmes target only 12% of young adolescent 
females worldwide, while the remaining females will 
miss the opportunity for vaccination without rapid 
roll-out of the HPV vaccine. Many countries in Africa 
and Asia, representing most of the population worldwide, 
have highly vulnerable populations at very high risk of 
developing cervical cancer and other HPV-related 
diseases. HPV vaccination might be the only feasible 
prevention strategy in those settings, with the great 
potential to narrow inequalities. The support of GAVI is 
becoming a crucial driving force in expansion of access 
in the coming years. However, upper-middle-income 
countries and half of lower-middle-income countries fall 
outside GAVI eligibility criteria. Aﬀ ordability and 
programmatic issues of HPV vaccine introduction are 
major obstacles in most of these settings that require full 
attention and probably international support. The 
reduction of doses required could be a crucial issue. The 
magnitude of cervical cancer cases that could be averted 
by HPV vaccination emphasises the need to implement 
HPV immunisation programmes, which might become 
the only realistic opportunity to reduce present 
inequalities in cancer risk.
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